Cerulean Pharma Inc. (CERU) Sees Unusually-High Trading Volume
Cerulean Pharma Inc. (NASDAQ:CERU) saw unusually-strong trading volume on Tuesday . Approximately 83,508 shares changed hands during trading, an increase of 15% from the previous session’s volume of 72,307 shares.The stock last traded at $2.14 and had previously closed at $2.18.
Several research analysts have weighed in on CERU shares. Canaccord Genuity reaffirmed a “buy” rating and set a $15.00 target price on shares of Cerulean Pharma in a research note on Wednesday, April 20th. Wedbush reaffirmed an “outperform” rating and set a $9.00 target price on shares of Cerulean Pharma in a research note on Tuesday, April 19th. Leerink Swann reaffirmed a “buy” rating on shares of Cerulean Pharma in a research note on Sunday, June 26th. Finally, Janney Montgomery Scott started coverage on shares of Cerulean Pharma in a research note on Wednesday, June 1st. They set a “buy” rating for the company. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Cerulean Pharma presently has an average rating of “Buy” and an average target price of $9.28.
The stock has a 50 day moving average of $2.24 and a 200 day moving average of $2.52. The firm’s market cap is $58.83 million.
Cerulean Pharma (NASDAQ:CERU) last posted its quarterly earnings results on Monday, May 2nd. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.06. Equities analysts expect that Cerulean Pharma Inc. will post ($1.80) EPS for the current fiscal year.
Cerulean Pharma Inc is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform utilizes nanoparticle-drug conjugates (NDCs), which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.